Notice of NIDA Participation in PA-18-653 "Developmentally Tailored HIV Prevention and Care Research for Adolescents and Young Adults (R34 Clinical Trial Optional)"

Notice Number: NOT-DA-18-005

Key Dates
Release Date: February 15, 2018

Related Announcements
PA-18-653

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

The purpose of this Notice is to inform potential applicants that the National Institute on Drug Abuse (NIDA) will participate, effective immediately, in PA-18-653, "Developmentally Tailored HIV Prevention and Care Research for Adolescents and Young Adults (R34 Clinical Trial Optional)" .
 
The following sections of PA-18-653 (shown in italicshave been updated to reflect the participation of the NIDA in this Funding Opportunity Announcement (FOA).
 
Part 1. Overview Information
 
Components of Participating Organizations
National Institute of Mental Health (NIMH)
National Institute on Drug Abuse (NIDA)

Catalog of Federal Domestic Assistance (CFDA) Number(s)
93.242, 93.279
 
Section VII. Agency Contacts
Scientific/Research Contact(s) 
Richard A. Jenkins, PhD
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-1923 
Email: jenkinsri@mail.nih.gov
 
Financial/Grants Management Contact(s) 
Edith Davis
National Institute on Drug Abuse (NIDA)
Telephone: 301-827-6697
Email: edavis1@nida.nih.gov
 
 
All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Richard A. Jenkins, PhD
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-1923
Email:
jenkinsri@mail.nih.gov